Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold
- Details
- Category: Abbott
Abbott (NYSE: ABT) has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years,
Genzyme Statement on Discussions With Sanofi-Aventis
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported today that discussions between its financial advisors and financial advisors for Sanofi-Aventis are continuing and have expanded to include representatives of both companies.
US Food and Drug Administration extend review timeline for vandetanib
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for the investigational drug vandetanib.
KOMBIGLYZE™ XR Now Available in U.S. Pharmacies
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.
FDA grants supplemental approval for ACTEMRA
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States (U.S.) Food and Drug Administration (FDA) has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function,
Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) and Xencor, Inc. will collaborate to develop XmAb(R)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.
Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines
- Details
- Category: Nycomed
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has included roflumilast (Daxas®) as a new treatment option in its COPD management guidelines. A section on the new class, phosphodiesterase 4 (PDE4) inhibitors, describes the efficacy of roflumilast in patients with COPD.
More Pharma News ...
- Merck KGaA Acquires Supplier to Biopharma Industry in China
- GSK responds to 60 Minutes | Related Video
- First two clinical phase III studies confirm the profile of nalmefene
- European Commission approves Tasigna® for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
- Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery Technology
- Pfizer Submits Applications to Expand the Use of Prevnar 13® to Adults 50 and Older
- Novo Nordisk A/S and Emisphere Technologies, Inc. Announce Licence Agreement